| Literature DB >> 30881272 |
José Antonio Delgado1, Daniel Morell-Garcia1,2, Josep Miquel Bauça1,2.
Abstract
BACKGROUND: Despite many studies assessing hemolysis interference in almost every clinically relevant magnitude, sodium has poorly been assessed. Our aim was to evaluate hemolysis interference on plasma sodium, using different strategies of hemolysis preparation, at different baseline sodium ion concentrations and bias specifications.Entities:
Keywords: hemolysate; hyponatremia; interference; interferogram
Year: 2019 PMID: 30881272 PMCID: PMC6416812
Source DB: PubMed Journal: EJIFCC ISSN: 1650-3414
Figure 1Strategies for the evaluation of hamolysis interference
Repeatability (coefficients of variation) of hemolysis index obtained by different strategies
| Plasma [Na+] | Low Hemolysis Assay | High Hemolysis Assay | |
|---|---|---|---|
| Strategy 1 | 144.1 | 0.26-0.78% | 0.28-0.44% |
| Strategy 2 | 144.3 | 0.57-48.6% | 0.40-135.1% |
Figure 2Interferograms for different sodium concentrations using both hemolysis preparing strategies
Comparison of slopes and intercepts of interferograms obtained at a specified sodium concentration (y: deviation from baseline as %; x: free hemoglobin in g/dL)
| Plasma [Na+] | Regression equation strategy 1 | Regression equation strategy 2 | p-value |
|---|---|---|---|
| 130 | y = –0.003x+0.088 | y = –0.004x∓0.136 | <0.001 |
| 135 | y = –0.002x–0.198 | y = –0.003x∓0.076 | 0.068 |
| 140 | y = –0.002x–0.272 | y = –0.003x+0.013 | 0.002 |
| 145 | y = –0.002x–0.190 | y = –0.004x∓0.046 | 0.001 |
* Significant at p<0.05
Hemolysis interference cut-off on plasma sodium for different bias specifications
| Free hemoglobin (g/dL) | |||||
|---|---|---|---|---|---|
| [Na+] | [Na+] | [Na+] | [Na+] | ||
| CI for samples used in Strategy 1 | (130.7-133.0) | (136.2-137.7) | (140.3-142.7) | (145.6-148.5) | |
| CI for samples used in Strategy 2 | (131.7-133.1) | (135.7-137.7) | (139.3-142.5) | (145.8-147.0) | |
| RCV | Strategy 1 | 0.95 | 0.96 | 0.99 | 1.04 |
| Strategy 2 | 0.61 | 0.86 | 0.77 | 0.70 | |
| RiLiBÄK | Strategy 1 | 1.13 | 1.17 | 0.93 | 0.84 |
| Strategy 2 | 0.74 | 1.04 | 0.93 | 0.84 | |
| Westgard | Strategy 1 | 0.30 | 0.22 | 0.20 | 0.24 |
| Strategy 2 | 0.15 | 0.23 | 0.23 | 0.21 | |
| RCPA-QAP | Strategy 1 | 0.88 | 0.84 | 0.81 | 0.86 |
| Strategy 2 | 0.56 | 0.76 | 0.65 | 0.59 | |
| CLIA | Strategy 1 | 1.17 | 1.17 | 1.17 | 1.17 |
| Strategy 2 | 1.17 | 1.17 | 1.17 | 1.17 | |
Confidence intervals are shown in parentheses. Abbreviations: RCV: reference change values; RCPA-QAP: Royal College of Pathologists of Australasia Quality Assurance Program.